Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Page 2

Mirum processes $75m IPO
Mirum Pharmaceuticals has raised $75m in its initial public offering that had an initial target of $86.3m and provided exits to Novo and Shire.
Fulcrum fulfils IPO dream
GlaxoSmithKline, Sanofi and 6 Dimensions Capital have all secured exits as the rare disease treatment developer raised $72m in its initial public offering.
Douyu wins $775m IPO game
Tencent-backed Douyu has successfully listed on Nasdaq after completing a $775m initial public offering that came after economic tensions forced a delay earlier this year.
IndiaMart takes stock of public market
IndiaMart, backed by Intel Capital and Brand Equity Treaty, has listed on the National Stock Exchange after raising $69m in its initial public offering.
Karuna caps off initial public offering
PureTech Health spinoff Karuna Therapeutics has upscaled its IPO to nearly $103m, after its shares rose by more than 50% in its first days of trading.
Morphic takes more money in $104m IPO
The corporate-backed small molecule therapeutic developer has boosted its initial public offering from $90m to nearly $104m.
Karuna kicks its way into public markets
PureTech Health-backed neuropsychiatric drug developer Karuna Therapeutics raised $89.2m in an upsized offering that followed $123m in venture capital.
BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
Adaptive Biotechnologies shapes $300m IPO
Shares in Adaptive Biotechnologies, backed by Microsoft, Celgene, Illumina, LabCorp and BD Biosciences, soared more than 100% on its first day of trading.
The RealReal realises IPO plans in $300m offering
Novel Group-backed luxury goods marketplace The RealReal will raise $300m in an initial public offering in which it will float above its range.

test reg